Immunic of Germany Set For Nasdaq After Merger With Failed Vital Therapies
The demise of Vital after a crushing late-stage failure has given Immunic the opportunity to cross the Atlantic and grow its business and pipeline.
The demise of Vital after a crushing late-stage failure has given Immunic the opportunity to cross the Atlantic and grow its business and pipeline.